Eli Lil­ly part­ners with Alzheimer's cen­ter for PhI­II study; New tu­ber­cu­lo­sis con­sor­tium emerges in $218M+ project

As Eli Lil­ly preps to sub­mit its Alzheimer’s can­di­date do­nanemab to the FDA fol­low­ing Bio­gen’s Aduhelm ap­proval, the Big Phar­ma is work­ing to col­lab­o­rate with a Phoenix re­search in­sti­tute to ad­vance the pro­gram’s Phase III study.

Lil­ly will team up with the Ban­ner Alzheimer’s In­sti­tute to see whether do­nanemab can slow clin­i­cal pro­gres­sion, the com­pa­ny an­nounced Thurs­day. Ban­ner will sup­port the en­roll­ment of tri­al par­tic­i­pants with and with­out the e4 type of apolipopro­tein E.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER